Brain scan study of an experimental tablet
This study tests a new tablet (LG-0317) to see how it affects a brain chemical called serotonin. The study uses a special brain scan to measure this effect in healthy volunteers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be a healthy male aged 18 to 45 years.
- Weigh at least 50 kg (110 pounds) and have a body mass index (BMI) between 19 and 28.
- Be willing to take the study tablet and undergo brain scans (PET/CT and MRI).
- Have no major medical conditions, including brain, heart, liver, kidney, or mental health disorders.
- Not be taking any prescription or over-the-counter medications, supplements, or herbal remedies within 14 days of the first dose.
- Avoid alcohol, caffeine, grapefruit, and smoking for a certain period before the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study tests a new experimental drug called LG-0317 in healthy volunteers to see if it is safe and how the body processes it. If you are healthy and meet the basic requirements, this trial may help advance a new treatment option.
This study tests a single dose of a new tablet medication (called TRTL-729) in healthy adults. It helps researchers learn how the drug is absorbed and tolerated, which is a first step in developing a treatment.
This early-stage study tests how a new experimental medication (HSK55879) is tolerated and processed by the body in healthy volunteers. Researchers will also check how food affects the drug's absorption to help determine safe dosing for future patient studies.
This study tests a new tablet in healthy adults to see how the body processes it and whether food changes its effects. It helps determine the right dose and safety for future patients.
This study uses a special brain scan to see how well a new medication attaches to brain receptors. It may help find better treatments for schizophrenia.
This is an early-stage safety study testing a new experimental tablet called SYH2072 in healthy volunteers. Researchers will give increasing doses to understand how safe it is, how your body processes it, and what effects it has.
Hear when a new Healthy Volunteers (HV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.